WASHINGTON (AP) -- A former blockbuster diabetes pill which was subjected to major safety restrictions in 2010 may not be as risky as once thought, according to the latest analysis of the much-debated GlaxoSmithKline drug.
The Food and Drug Administration is reviewing a new interpretation of the key study of Avandia's heart attack risks, which suggests the drug is as safe as older diabetes drugs. At a highly unusual meeting this week, the FDA will ask a panel of experts to vote on a range of options for the drug, including lifting restrictions that limit which patients can get a prescription.
The positive safety review from Duke University researchers is the latest twist in a years-long debate over Avandia, which has divided medical experts, cost Glaxo billions of dollars and possibly resulted in an unknown number of patient heart attacks.
First approved in 1999, Avandia became the top-selling diabetes pill in the world by 2006 with sales of $3.4 billion. But prescriptions plummeted the following year after an analysis of dozens of studies suggested Avandia could raise the risk of heart attack.
For three years the FDA struggled to answer a seemingly simple question: Does Avandia increase the risk of heart attacks? A definitive answer has never been reached, in part because patients with diabetes are already predisposed to heart attacks. That makes it extremely difficult to tell which heart problems are drug-related and which are simply a result of the underlying disease.
Finally in 2010 the FDA decided to restrict the drug's use to all but the rarest of cases. Regulators in Europe banned the drug outright.
The FDA's safety restrictions will get a second look at a meeting this Wednesday and Thursday prompted by a new analysis of the lone study designed to assess Avandia's heart risks. Known as RECORD, the study followed 4,400 patients and tracked rates of heart attack, hospitalization and death for six years.
The results were first reported in 2009 and medical experts have been debating their legitimacy ever since.
At the last Avandia panel meeting in 2010, FDA leadership generally backed RECORD's findings that Avandia appeared as safe as other standard diabetes drugs. But FDA staff scientists said the study was unreliable because of underreported heart attacks and other design flaws. Because of that disagreement the FDA asked Glaxo to obtain an independent analysis by an outside party.
The new analysis by the Duke Clinical Research Institute generally supports Glaxo's original findings. In documents posted Monday, an FDA review of Duke's analysis states: "These results show no statistically significant evidence to suggest an increased cardiovascular risk."
Despite that assessment, the FDA documents state that the agency "has not reached any final updated conclusions" on the heart safety of Avandia.
The FDA will seek advice from two panels comprised of outside experts in diabetes and drug safety. The panelists will be asked to vote on four options for Avandia:
— Removing the drug's safety restrictions
— Leaving the safety restrictions in place
— Modifying the safety restrictions
—Withdrawing the drug from the market entirely
At the last FDA meeting on Avandia in 2010, the panelists voted 21 to 12 to leave Avandia on the market. The group's recommendations are not binding and are only one part of the government's decision-making process.
U.S. shares of GlaxoSmithKline PLC rose 13 cents to $51.90 in morning trading Monday. They traded as high as $54 last Tuesday and are up almost 25 percent from their 52-week low of $41.68 last November.